Exp Neurol. 2003 Dec;184(2):912-22
Magy L, Mertens C, Avellana-Adalid V, Keita M, Lachapelle F, Nait-Oumesmar B, Fontaine B, Baron-Van Evercooren A.
INSERM U546, Laboratoire des Affections de la Myeline et des Canaux Ioniques Musculaires, Faculte de Medecine Pitie-Salpetriere, IFR 70, CHU Pitie-Salpetriere, 75634 Paris Cedex 13, France.
Transplantation of glial cells into the central nervous system (CNS) may be a promising approach for the treatment of myelin disorders such as multiple sclerosis (MS).
Myelination by transplantation of oligodendrocyte precursors has been obtained in different animal models of demyelination.
A strategy to favor CNS remyelination is to enrich the lesioned areas in growth factors to stimulate the quiescent population of oligodendrocyte precursors.
In this context, we have developed a genetically modified CG4 cell line (CG4-FGF2), which are able to release significant amounts of fibroblast growth factor 2 (FGF2) in a controlable fashion in vitro.
The data presented here demonstrate that upon induction with Dox, CG4-FGF2 cells retain their capacity to differentiate in vitro.
Additionally, we provide evidence that FGF2 release by engineered cells enhance proliferation and migration of cells of the oligodendrocyte lineage without preventing them to differentiate and myelinate axons in vitro.